Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tome Biosciences
Gene editor biotech that emerged in 2023 with $213 million
Biotech
Biopharma layoff rate stabilizes in Q3: Fierce Biotech analysis
August saw a surge in workforce reductions, with 21 rounds reported, compared to July’s 17 and September’s 11.
Gabrielle Masson
Oct 4, 2024 3:50pm
Gene editor Tome laying off 131 workers
Aug 26, 2024 11:03am
8 months after $213M fundraise, gene editor Tome cuts costs
Aug 22, 2024 2:57pm
